John Bencich was named Chief Financial Officer of AEON Biopharma, Inc., effective March 9, 2026. As of November 14, 2026, AEON Biopharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 9, 2026, naming 1 appointment (Form 8-K, March 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like AEON Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
AEON Biopharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as AEON Biopharma, Inc. files it.
Also on the record for AEON Biopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| November 10, 2026 | Stake report, Schedule 13D/A, by Daewoong Co., Ltd. | 30.6% of the class | 5%+ stakes | Source |
| August 21, 2026 | Stake report, Schedule 13G, by Timothy P. Lynch | 13% of the class | 5%+ stakes | Source |
| July 21, 2026 | Stake report, Schedule 13G, by Stonepine Capital Management, LLC | 9.9% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13D, by Daewoong Co.,Ltd. ("DWC") | 49.99% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13D/A, by Daewoong Co.,Ltd. ("DWC") | 0.9% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13G/A, by Alta Partners LLC | 2.1% of the class | 5%+ stakes | Source |
| July 9, 2025 | Stake report, Schedule 13G/A, by Alta Partners LLC | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs AEON Biopharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on AEON Biopharma, Inc. and the records around it.
AEON Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Timothy P. Lynch also filed stake reports on 1 other company: Evolus, Inc. (Feb 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
Watch AEON Biopharma, Inc.
Get an email when AEON Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on AEON Biopharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on AEON Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AEON Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-09 | In | Chief Financial Officer | 2026-03-09 | 8-K, 2026-03-09 |
Who leads AEON Biopharma, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: John Bencich, appointed, effective 2026-03-09 (filed 2026-03-09).
New leaders reset buying decisions — get the Full Report on AEON Biopharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at AEON Biopharma, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at AEON Biopharma, Inc.Every change, in the filing's words
Appointed: John Bencich, Chief Financial Officer, effective 2026-03-09
On March 6, 2026, the Board of Directors of AEON Biopharma, Inc. ("AEON" or the "Company") appointed John Bencich, age 49, as the Company's Chief Financial Officer, effective as of March 9, 2026 and principal financial officer, effective as of April 1, 2026.
- Mr. Bencich's appointment is part of the Company's strategic plan to strengthen its executive leadership team as it advances key regulatory and financing milestones.
- Mr. Bencich brings more than 25 years of financial and leadership experience in the biotechnology and life sciences sectors, having led corporate finance, SEC reporting, capital markets transactions, strategic planning, and operational scaling initiatives across emerging growth and publicly traded companies.
- Prior to joining the Company, Mr. Bencich served as Chief Executive Officer of Achieve Life Sciences from September 2020 to August 2024 and as Executive Vice President and Chief Operating Officer from August 2017 to August 2020.
- Mr. Bencich served as Vice President and Chief Financial Officer of Oncogenex Pharmaceuticals from August 2014 to September 2017 until its merger with Achieve Life Sciences.
- From September 2012 to August 2014, he served as Chief Financial Officer of Integrated Diagnostics.
- Prior to joining Integrated Diagnostics, he served as Chief Financial Officer of Allozyne, Inc., and the Vice President, Chief Financial Officer and Treasurer of Trubion Pharmaceuticals, Inc. Earlier in his career, Mr. Bencich held roles at Onyx Software Corporation, a publicly traded software company, and Ernst & Young LLP an international professional services firm.
Tools for this story
Each opens in a new tab, filled in for AEON Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
